Sign In
Buy BHC
$4.95
-0.0600 (-1.20%)
At Close: Jun 03, 2026
Why Bausch Health (BHC) Might Surprise This Earnings Season
02:45pm, Wednesday, 05'th Aug 2020
Bausch Health (BHC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Bausch Health Resolves Canadian Securities Class Action
11:00am, Wednesday, 05'th Aug 2020
Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company"), today announced that the parties in the Canadian securities class action (Cattuci et al. v. Valeant Pharmaceuticals Int
Bausch Health to pay $45 million fine to settle Philidor charges
09:30pm, Friday, 31'st Jul 2020
Bausch Health Cos. will pay a $45 million fine to settle charges that the company misled investors in financial statements when it was known as Valeant Pharmaceuticals, according to the Securities an
Bausch Health, three former executives agree to penalties to resolve U.S. SEC charges
08:51pm, Friday, 31'st Jul 2020
Bausch Health Companies Inc has agreed to pay $45 million, and three of former top executives also agreed to penalties, to settle charges of improper revenue recognition and misleading disclosures in
Bausch Health Resolves Legacy SEC Investigation
08:43pm, Friday, 31'st Jul 2020
Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company"), f/k/a Valeant Pharmaceuticals International, Inc. ("Valeant"), today announced the successful resolution of the legacy
Earnings Preview: Bausch Health (BHC) Q2 Earnings Expected to Decline
04:33pm, Thursday, 30'th Jul 2020
Bausch (BHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Capital Interviews: Gerald Posner Discusses His New Book On Pharma, The Pandemic, And The Future Of The Industry
04:27pm, Wednesday, 15'th Jul 2020
Author Gerald Posner discusses his latest book, a history of the pharmaceutical industry. How the Sackler family had a larger influence on the development of the industry than most had previously unde
What We Learned About Bausch Health Companies' (NYSE:BHC) CEO Compensation
02:03pm, Tuesday, 14'th Jul 2020
Joseph Papa became the CEO of Bausch Health Companies Inc. (NYSE:BHC) in 2016, and we think it's a good time to look...
It's Been A Rough 6 Months For Stock-Picking Gurus
06:22am, Tuesday, 14'th Jul 2020
Some of the best stock-pickers working today are having a rough go of it. It's not surprising that many of them are struggling, just as the rest of us mere mortals are.
Did Hedge Funds Make The Right Call On Bausch Health Companies Inc. (BHC) ?
01:23am, Friday, 10'th Jul 2020
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (see why hell is coming). In these volatile market
Bausch Health: Setting Its Sights On Eye Care
06:14am, Friday, 03'rd Jul 2020
Bausch Health highlighted the positive progress of its contact lens business. Near-term slowdown from COVID-19 is coming to an end. Fair value models have an ov
Bausch Health: Investors Were Acknowledging The Turnaround Before COVID-19 Struck
05:22pm, Thursday, 02'nd Jul 2020
From 2015-2016, BHC lost roughly 90% of its stock value due to the Company’s destructive acquisition strategy—purchasing drugs and inflating their prices—which
Bill Ackman on Becoming an Activist Investor
10:37pm, Monday, 29'th Jun 2020
The veteran investor also reflects on principles to embrace Continue reading...
Sol-Gel Technologies Announces Agreements with Perrigo Company for Three New Generic Product Candidates
11:00am, Monday, 29'th Jun 2020
Sol-Gel Technologies, Ltd. (SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin disea
Moves by Bill Ackman, Jeffrey Ubben Indicate Change Is Afoot in the World of Hedge Funds
10:17pm, Thursday, 25'th Jun 2020
Pershing Square’s Bill Ackman has formed a giant special purpose acquisition company to snag a “mature unicorn.” ValueAct’s Jeffrey Ubben left the fund he founded to fully dive into ESG.
